Prothena Corporation plc (LON:0Y3M)

Market Cap	662.32M
Revenue (ttm)	107.96M
Net Income (ttm)	-97.70M
Shares Out	n/a
EPS (ttm)	-1.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,512
Average Volume	874
Open	15.91
Previous Close	15.09
Day's Range	14.78 - 16.77
52-Week Range	9.16 - 33.05
Beta	0.08
RSI	60.68
Earnings Date	Feb 14, 2025

About Prothena Corporation

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 173
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0Y3M

Financial Performance

In 2023, Prothena Corporation's revenue was $91.37 million, an increase of 69.50% compared to the previous year's $53.91 million. Losses were -$147.03 million, 25.7% more than in 2022.

Financial numbers in USD